Cowen & Co. Maintains Outperform on AbbVie, Raises Price Target to $98

Cowen & Co. analyst Steve Scala maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $90 to $98.

Benzinga · 12/26/2019 13:27

Cowen & Co. analyst Steve Scala maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $90 to $98.